Evogene (EVGN) Change in Account Payables (2013 - 2026)
Evogene (EVGN) posted Change in Account Payables of -$115000.0 for Q1 2026, down 161.17% sequentially from $188000.0 in Q4 2025, and up 62.42% YoY from -$70804.8 in Q1 2025.
Evogene (EVGN) Change in Account Payables (2013 - 2026) Analysis & Trends
Evogene has reported Change in Account Payables for 14 years, with the latest figure at -$115000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 62.42% year-over-year to -$115000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68000.0 (up 77.26% YoY) and the FY2025 annual result came in at -$259000.0, up 58.89% from the prior year.
- Change in Account Payables slipped to -$115000.0 in Q1 2026 per EVGN's latest filing, from $188000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $563000.0 in Q4 2023 and troughed at -$685000.0 in Q1 2024.
- A 5-year average of -$45823.5 and a median of -$78000.0 in 2025 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 329.77% in 2023, down 1483.33% in 2023.
- Over 5 years, Change in Account Payables stood at $131000.0 in 2022, then surged by 329.77% to $563000.0 in 2023, then tumbled by 129.48% to -$166000.0 in 2024, then surged by 213.25% to $188000.0 in 2025, then sank by 161.17% to -$115000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$115000.0, $188000.0, and -$78000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -115,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -115,000.00 |
| Mar 31, 2026 | -115,000.00 |
| Dec 31, 2025 | 188,000.00 |
| Dec 31, 2025 | 188,000.00 |
| Sep 30, 2025 | -78,000.00 |
| Sep 30, 2025 | -78,000.00 |
| Jun 30, 2025 | -63,000.00 |
| Jun 30, 2025 | -63,000.00 |
| Mar 31, 2025 | -306,000.00 |
| Mar 31, 2025 | -306,000.00 |
| Dec 31, 2024 | -166,000.00 |
| Dec 31, 2024 | -166,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Jun 30, 2024 | -79,000.00 |
| Jun 30, 2024 | -79,000.00 |
| Mar 31, 2024 | -685,000.00 |
| Mar 31, 2024 | -685,000.00 |
| Dec 31, 2023 | 563,000.00 |
| Dec 31, 2023 | 563,000.00 |